In this study, we explore the predictive power of bioactivity, alongside features that represent the drug's chemical and pharmacological properties. Each trial has a candidate drug and an indication. Common protein targets between the drug and the indication are retrieved using the databases and methods described in Section 2. We show that using an aggregate activity value of common targets between drug and disease is a powerful indicator of clinical trial success, even with the challenges and ambiguity involved in bioactivity classes.